New startup ideas · Health and bio · Healthcare and bio
startup idea
Substrate Exchange
The exchange where pharma buys the experimental data that trains biology models.
Substrate Exchange is a marketplace where biotechs, CROs and academic labs list assay results, screening runs and failed-experiment data in standardized, model-ready form, and pharma AI teams license it by the dataset or by subscription.
- Marketplace
- Enterprise
- $100B+ market
- Creates a new category
- US first
4/5
venture judge
4
similar startups, last 2 years (11 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,000 · 5 weeks · 20 prospects
For $1,000 and 5 weeks, prove AI drug discovery teams will pay real invoices for standardized, non-exclusive assay data and that generators will list it on shared rails.
Riskiest assumption · Pharma and biotech AI teams will license standardized assay data non-exclusively at marketplace prices, instead of demanding the exclusive bilateral deals they buy through today.
1Focus group: who and where
Head of ML or computational biology at a US AI drug discovery company, seed to Series B with 10-60 people, whose model roadmap this quarter needs more assay volume than their wet lab or CRO budget can generate.
where to find 20 · The Bits in Bio Slack community of techbio builders; the YC startup directory filtered to biotech and drug discovery companies in the S25-S26 batches, including Rasyn, WonderTx and Atlas Discovery from the card; the speaker and sponsor lists of the Bio-IT World Conference & Expo in Boston, scrapable today for exact names and titles.
2Sell first, build later
A design-partner data pilot: one defined assay dataset slice from a named generator, normalized to the buyer's schema with full provenance documentation, delivered within 14 days of payment, plus six months of first access to new catalog listings.
the ask · $2,500 per pilot, credited in full against a first annual catalog license.
a real yes · A real yes is a paid $2,500 invoice or a countersigned pilot scope with a payment date; 'send us the schema', free-sample requests and dataset wishlists do not count.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Exclusivity and price interviews
$100 · 10 days
Book 12 calls with ML leads sourced from Bits in Bio and the YC directory. Ask what external data they last bought, at what price, and whether exclusivity was required, then show a one-page sample catalog sheet at three price points and ask which they would sign today.
keep going if · 8 of 12 bought external data in the past year, and 6 of 12 accept non-exclusive terms at a 40-60 percent discount to a commissioned run
2. Supply listing MOUs
$300 · 14 days
Pitch 5 automated data generators, starting with elegslab from the card, on a non-exclusive listing agreement at a 15-20 percent take rate, using a lawyer-reviewed one-page MOU. Get one sellable sample dataset with provenance documentation out of the signings.
keep going if · 3 of 5 generators sign a listing MOU and hand over a sellable sample dataset
3. Paid data pilot sales
$600 · 14 days
Turn the sample into a $2,500 paid pilot: a defined dataset slice normalized to the buyer's schema, delivered in 14 days, fee credited against a first annual license. Pitch it to 10 of the interviewed teams with an invoice attached to the scope.
keep going if · 3 of 10 teams pay the $2,500 pilot invoice
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$2,500
per prospect, refundable
how · A prepaid design-partner pilot invoiced up front with net-7 terms; these buyers already pay CROs and data vendors by invoice, so an invoice against a one-page signed scope is the credible instrument, not a consumer checkout. The buyer's ML lead signs the scope, the generator has already signed the listing MOU. set up: Stripe Invoicing ↗
what it reserves · A normalization slot: the agreed dataset slice in the buyer's schema within 14 days, provenance documentation included, and six months of first access to each new catalog listing; the fee is credited in full against a first annual license.
refund · Refunded in full if delivery misses the agreed schema spec or the 14-day delivery date.
target · 3 paid pilots from 10 pitched teams within 21 days of the sample catalog going live
Go: build it if
3 or more paid $2,500 pilots, 3 signed generator MOUs, and at least 6 of 12 buyers accepting non-exclusive terms: build the exchange and the normalization pipeline.
Kill: stop if
Fewer than 2 pilots paid after 10 pitches, or a majority of buyers insisting on exclusivity: the market collapses back into bilateral brokerage the card set out to replace, stop.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
Your models need more assay volume than your wet lab budget can generate, and buying it today means a months-long bilateral deal with one CRO. I'm building a catalog of standardized, provenance-tracked assay datasets from automated generators, starting with high-volume C. elegans screening data, licensed non-exclusively at a fraction of a commissioned run. First pilots are $2,500 for a defined slice in your schema, delivered in 14 days and credited against a license. Got 20 minutes this week to see if the schema fits your training pipeline?
landing page
Model-ready assay data, licensed by the dataset, not the deal cycle. $2,500 pilot: a defined data slice in your schema within 14 days, credited to your first annual license. Book a pilot scoping call.
deposit terms
The $2,500 pilot fee is invoiced up front and reserves your normalization slot: a defined dataset slice delivered in your schema within 14 days, with full provenance documentation. It is refunded in full if delivery misses the agreed spec or date. The fee is credited against your first annual catalog license.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
90
Idea Score, 0-100 · raw 56.0 x 1.61
Warm
competition: more crowded than 41% of ideas · headwind x0.80
+4.2
government priorities, secondary (59 matching grants)
Trend
85
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)96
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst75
Demand
54
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)83
- Operator judge: real pain50
100x potential
60
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis80
- Neighbours still alive5
- Technologist judge25
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were exchange, pharma, buys, experimental, trains, biology, substrate, marketplace.
The idea in full
- What
- Substrate Exchange is a marketplace where biotechs, CROs and academic labs list assay results, screening runs and failed-experiment data in standardized, model-ready form, and pharma AI teams license it by the dataset or by subscription. The company handles normalization, provenance and pricing, and takes a percentage of every license - pure software margins on other people's wet-lab spend.
- Why now
- Five companies from the last two years pitch 'drug discovery' and the S26 batch alone funded Rasyn, WonderTx and Atlas Discovery, all building predictive models for chemistry and trials - the models are commoditizing while proprietary training data has become the scarce input, and today it changes hands only in slow bilateral deals.
- Wedge: first customer and entry point
- Sign three to five automated data generators as exclusive supply - platforms like elegslab, which mass-produces C. elegans assay data - and sell that catalog founder-to-founder to the AI drug discovery companies that need volume they cannot generate in-house.
- Path to 100x
- Pharma R&D spend exceeds $100B a year, and the share flowing into model training data is growing from near zero; the first liquid exchange sets the standards, holds the exclusive supply contracts, and earns a take rate on a new asset class it defined. Catalog exclusivity is the distribution moat - once the best data only trades here, buyers and sellers both have to show up.
- Ceiling
- The largest data generators eventually go direct to the five biggest pharma buyers, capping the exchange at the long tail of the market.
- Closest real companies, as the generator saw them
- Rasyn, WonderTx and Atlas Discovery are model builders and natural buyers, not exchanges; elegslab generates assay data at scale but sells it one contract at a time. Substrate Exchange is the many-to-many market none of them operates.
- Main risk
- Pharma buyers demand exclusivity on every dataset, collapsing the marketplace back into the bilateral brokerage it was meant to replace.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Capital-light take rate on a new asset class carved out of $100B+ pharma R&D spend, with exclusive supply as the wedge.
Bootstrapper
4/5
Pure take rate on other people's wet-lab spend, pharma already pays for data in slow bilateral deals, revenue inside a year or two.
Operator
3/5
Pharma AI teams already buy this data bilaterally, so the spend exists, but sellers going direct to the five big buyers is the normal outcome.
Technologist
2/5
Normalization and provenance on other labs' assay data is light engineering; the asset is exclusive supply contracts with generators like elegslab, not technology.
Risk
2/5
Supply concentrates in three to five exclusive generators and demand in five big pharma buyers, so either side going direct ends the exchange.
trends
4/5
Rests on the 2025-2026 flip where models like Rasyn commoditize while proprietary training data becomes the scarce input - a still-unclaimed window.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (exchange, pharma, buys, experimental, trains, biology, substrate, marketplace): 11 all-time, 4 from the last two years. Same matching as Idea Check.
Frontier grows scalable biological brains as an ML training substrate
Extrapolative AI to unlock First-in-Class drugs
Real world training envs for healthcare AI models
RNA intelligence for precision medicine
A marketplace for vinyl, cassettes and cds
Operator of a peer-to-peer fashion marketplace intended to connect buyers and sellers for online shopping. The company offers a marketplace that is a mix of a social network and a forum where people like and comment on the articles posted and give each other fashion tips, enabling customers to buy, sell, exchange, and review new and used fashion items with ease.
First End-to-End B2B supplies platform for pharmacies in Egypt.
GearUp is a peer to peer marketplace for creatives to buy and sell new and used creative equipment.
Shibuya Blend Green Energy is a operator of a carbon trading platform.
Leading the immersive ecosystem for enterprise. The content aggregation, distribution and reporting platform.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
- A massively parallel cell-based platform for the rational discovery of molecular gluesawardhigh relevance
NIH / NIGMS · SBIR phase II · $349K · posted 2026-09-19
- CAREER: Multimodal Generative AI for Autonomous Biomolecular Design and Accelerated Discoveryawardhigh relevance
National Science Foundation · Info Integration & Informatics · $758K · posted 2026-05-25
NIH / NIGMS · SBIR phase II · $254K · posted 2025-09-30
National Science Foundation · Dynamics, Control and System D · $655K · posted 2026-08-17
- Collaborative Research: VINES: Track 1: ARMANI - AI-native RAN MANageability and Intelligence for Next Generation Networksawardmedium relevance
National Science Foundation · Use-Inspired NextG · $333K · posted 2026-07-29
- Collaborative Research: VINES: Track 1: ARMANI - AI-native RAN MANageability and Intelligence for Next Generation Networksawardmedium relevance
National Science Foundation · Use-Inspired NextG · $667K · posted 2026-07-29
- NSF PCL-Test Bed: A Cloud Lab with AI-Integrated Remote Experimentation (CLAIRE)awardmedium relevance
National Science Foundation · PCL-Programmable Cloud Labs · $20M · posted 2026-07-21
- Metabolomics-Guided Explorations of Wastewater Comamonas for Mixed Conversion of Aromatic Carbons in Lignin and Plastic Wastesawardmedium relevance
National Science Foundation · EnvE-Environmental Engineering · $495K · posted 2026-07-16
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Real engineering
- Go-to-market
- Founder-led sales
- Moat
- Distribution moat
- Geography
- US first
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.